Andere Sprachen Ascletis Pharma Inc.

Aktien

A2JRKN

KYG0520K1094

1672

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:09:00 03.05.2024			% 5 Tage	% 1. Jan.
1,42 ^HKD	+1,43 %		+5,97 %	-2,74 %

03.04.	Ascletis stellt Studien mit dem FXR-Agonisten gegen biliäre Cholangitis, NASH und Hepatitis-B-Virus ein	MT
03.04.	Ascletis Pharma Inc. gibt strategische Entscheidungen zum FXR-Agonisten ASC42 bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus	03.04.
Ascletis Announces Strategic Decisions on FXR agonist ASC42	03.04.
Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42	03.04.
Ascletis Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25.03.
Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting	11.03.
Ascletis Pharma Doses First Patient in Phase 3 Clinical Trial of Acne Vulgaris Drug	24.01.
Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne	24.01.
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne	24.01.
Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH	23.01.
Ascletis Pharma's Liver Treatment Reduces Fat in 9 of 10 Participants During Phase 2 Trial	03.01.
Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis	02.01.
Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis	02.01.
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 for Treatment of Acne	06.12.
Ascletis Pharma Gets Nod to Trial Acne Drug	05.12.
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne	05.12.
Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne	05.12.
Ascletis Pharma Presents Data on Studies for Liver Treatments at US Liver Disease Meet	13.11.
Ascletis Pharma Publishes Results of Gannex's Fatty Liver Medication	06.11.
Ascletis Pharma Presents Data in Germany from Phase 2 Study on Anti-Acne Drug	11.10.23
Ascletis Announces Poster Presentation of Phase II Study Topline Results of FASN Inhibitor ASC40 for Treatment of Acne at EADV Congress 2023	11.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ascletis Pharma Inc.

Aktien

A2JRKN

KYG0520K1094

1672

Andere Sprachen

Filter